We report a comparison of natural and synthetic vitamin E in humans using deuterium labeling to permit the two forms of vitamin E to be measured independently in plasma and tissues of each subject. Differences in natural and synthetic vitamin E concentrations were measured directly under equal dosage conditions using an equimolar mixture of deuterated RRR-␣-tocopheryl acetate and all-rac-␣-tocopheryl acetate. Two groups of five adults took 30 mg of the mixture as a single dose and as eight consecutive daily doses, respectively. After a 1-mo interval the schedule was repeated but with a 10-fold higher dose (ie, 300 mg). In each case, the ratio of plasma d 3 -RRR-␣-tocopherol to d 6 -all-rac-␣-tocopherol (RRR:rac) increased from Ϸ1.5-1.8 to Ϸ2 after dosing ended. In an elective surgery study in which 22 patients were given 150 mg/d for up to 41 d before surgery, the RRR:rac in tissues was lower than in plasma and the percentage of deuterated ␣-tocopherol was lower in all tissues except gallbladder and liver. In a terminally ill patient given 30 mg/d for 361 d, plasma and tissue (x -± SD) RRR-rac ratios (and % deuterated ␣-tocopherol) at autopsy were 2.06 (6.3%) and 1.71 ± 0.24 (5.9 ± 2.2%), respectively. In a second terminally ill patient given 300 mg/d for 615 d, the corresponding values were 2.11 (68%) and 2.01 ± 0.17 (65 ± 10%), respectively. The results indicated that natural vitamin E has roughly twice the availability of synthetic vitamin E. This 2:1 ratio is significantly higher than the currently accepted RRR:rac of 1.36:1.00. ␥-Tocopherol, expressed as a fraction of total unlabeled tocopherols in 15 elective surgery patients, was 1.4-4.6 (mean: 2.6) times greater in adipose tissue, muscle, skin, and vein than in plasma, which is a substantially larger fraction than had been recognized previously.
INTRODUCTION
␣-Tocopherol, vitamin E, is available commercially for use as a dietary supplement in both its natural, single stereoisomeric form (RRR, formerly d) and in a synthetic form (all-rac, formerly dl). The latter form consists of an approximately equimolar mixture of eight stereoisomers. Both forms of ␣-tocopherol are usually sold either as acetate esters (␣-tocopheryl acetate; TAc) or, less frequently, as succinate esters. According to a specific protocol, the acetate ester of the single, natural stereoisomer RRR-␣-TAc is 1.36 times more biologically potent than allrac-␣-TAc in rats (1) (2) (3) (4) (5) (6) . This relative potency factor of 1.36 is officially accepted (7) despite the fact that application of the same specific protocol to measure the relative potencies of RRR-␣-tocopherol and RRR-␣-TAc has been shown to yield results that are irrelevant to both humans and rats under normal dietary conditions (8) .
The higher biological activity of natural compared with synthetic vitamin E does not result from differences in intrinsic antioxidant activity. Burton and Ingold (9, 10) showed that the chromanol structure of vitamin E (Figure 1 ) controls inherent reactivity toward peroxyl radicals in vitro. Because the chromanol structure is identical in both natural and synthetic ␣-tocopherol, differences in the phytyl tail must determine the differences between these forms in vivo. The phytyl tail encompasses three chiral centers, which give rise to the eight stereoisomers of synthetic vitamin E (Figure 1 ). Animal assays provide evidence that the chiral center at the 2-position, the point at which the phytyl tail is bound to the chroman ring, is the major and possibly sole determinant of the biological differences between ␣-tocopherol stereoisomers. The lack of importance of the 4Ј and 8Ј chiral carbons is illustrated by the similar biopotencies of allrac-␣-tocopherol (RRR + RRS + RSR + RSS + SRR + SRS + SSR + SSS) compared with 2-ambo-␣-tocopherol (RRR + SRR) and of Human plasma and tissue ␣-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E 2R,4Ј-ambo-8Ј-ambo-␣-tocopherol (RRR + RRS + RSR + RSS) compared with RRR-␣-tocopherol. Furthermore, significantly higher biopotencies were found for RRR-␣-tocopherol than for 2-ambo-␣-tocopherol (1) (2) (3) 6) . Similarly, the vitamin E activity of the acetates of three 2RS-n-alkyl-2,5,7,8-tetramethyl-6-hydroxychroman analogues of ␣-tocopherol have been measured and compared directly with all-rac-␣-TAc, or indirectly with RRR-␣-TAc, using the rat curative myopathy, plasma pyruvate kinase assay (11) . The analogues with alkyl chain lengths of 11 and 13 carbons have activities that do not differ significantly from each other or from all-rac-␣-TAc. Thus, methyl branching in the phytyl tail at the 4Ј, 8Ј, and 12Ј positions has little influence on vitamin E activity.
To study how ␣-tocopherol stereochemistry affects plasma and tissue concentrations, we synthesized deuterated RRR-␣-tocopherols containing three or six deuterium atoms per molecule (12) (13) (14) and 2-ambo-and all-rac-␣-tocopherol with three, six, or nine deuterium atoms per molecule (14) . The deuterium atoms are located specifically in one or more of the three, nonlabile aromatic methyl positions: 5-CD 3 -␣-tocopherol (d 3 -␣-tocopherol); 5,7-(CD 3 ) 2 -␣-tocopherol (d 6 -␣-tocopherol); and 5,7,8-(CD 3 ) 3 -␣-tocopherol (d 9 -␣-tocopherol) ( Figure 1 ). The nonradioactive nature of deuterium and its nonlabile location in the molecule make deuterated vitamin E especially suitable for studies in humans (15) . A particularly useful feature of the deuterated vitamin E method is that ␣-tocopherols substituted with deuterium to discretely different extents (eg, d 3 and d 6 ) can easily be distinguished by mass spectrometry, which allows the relative concentrations of two or more forms of vitamin E to be evaluated simultaneously. This competitive technique, using two (or more) forms of vitamin E imbibed simultaneously, eliminates the statistical variability that individual animals (and humans) exhibit when they are dosed separately with different forms of vitamin E.
We previously measured vitamin E concentrations in human plasma and in plasma and tissues of experimental animals using gas chromatography-mass spectrometry (GC-MS) after administration of deuterated vitamin E (8, 12, (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Plasma concentrations of stereoisomeric forms of vitamin E are apparently dependent on the ability of the hepatic ␣-tocopherol transfer protein to select RRR-␣-tocopherol preferentially for secretion in nascent VLDL (12, (17) (18) (19) (20) (21) . Catabolism of VLDL in plasma results in the enrichment with RRR-␣-tocopherol of other circulating lipoproteins and hence, eventually, the tissues. The importance of the hepatic ␣-tocopherol transfer protein (17) (18) (19) (20) (21) is further indicated by recent studies of humans with neurologic defects (both isolated patients and a large kindred in Tunisia) that showed that a genetic defect in this protein leads to a severe vitamin E deficiency (26) . The rat ␣-tocopherol transfer protein has been purified and characterized (27) and the human form has been cloned and its chromosomal localization reported (28) .
The available experimental data (see above) suggest that the greater biological activity of natural relative to synthetic ␣-tocopherol is due to the preferential enrichment of VLDL with RRR-␣-tocopherol and subsequently of other lipoproteins, with ultimate delivery of RRR-␣-tocopherol to the tissues by these lipoproteins. To investigate these ideas further we measured plasma ␣-tocopherol (unlabeled and labeled) in healthy human volunteers after consumption of deuterated natural and synthetic forms of ␣-TAc, in the tissues from patients undergoing elective surgery, and in two terminally ill patients who daily consumed deuterated ␣-TAcs for 1 and 2 y, respectively, until death. 3 )tocopheryl acetate (d 3 -RRR-␣-TAc) and all-rac-␣-5,7-(CD 3 ) 2 tocopheryl acetate (d 6 -all-rac-␣-TAc) were synthesized by Eastman Kodak, Rochester, NY. The two compounds were determined by GC analysis to be 96% pure RRR-and 93% pure all-rac-␣-TAc, respectively. The isotopic purities at the nominal level of deuteration were 84% ( (8, (12) (13) (14) . A deuterated ␥-tocopherol, d 17 -␥-tocopherol, synthesized earlier (14) was used as described previously (20) as an internal standard for GC-MS determination of ␥-tocopherol in some tissues and blood obtained from subjects in the elective surgery study.
SUBJECTS AND METHODS

Deuterated tocopherols
RRR-␣-5-(CD
Kinetics of RRR-␣-tocopherols compared with all-rac-␣-tocopherols in human plasma
Studies were carried out at the NRC with two groups of five adult volunteers aged 20-59 y after informed consent had been obtained. The studies were designed to gather information on the effect of taking single and multiple doses in amounts that approximate those most commonly encountered by the general public who take supplements in the form of multivitamin pills and vitamin E capsules. One group consumed, with their evening meal, a single 30-mg dose of the encapsulated 1:1 mixture of d 3 -RRR-␣-TAc and d 6 -all-rac-␣-TAc. One month later this group consumed a 10-fold higher dose (300 mg) provided in the form of two capsules, each containing 150 mg of the same mixture. A second group received this mixture in eight consecutive daily doses of 30 mg, followed > 1 mo later by eight consecutive daily doses of 300 mg. A third group of five subjects consumed a single 100-mg dose of deuterated vitamin E in which the labeling of the two forms of vitamin E was reversed, ie, 50 mg d 6 -RRR-and 50 mg d 3 -all-rac-␣-TAc.
Blood samples from nonfasting subjects were drawn in the morning into Na 2 EDTA-coated evacuated tubes at the Ottawa branch of the Canadian Red Cross Society and immediately placed on ice for transport to and extraction at the NRC laboratory in Ottawa. During vitamin E dosing, blood was sampled daily, except during weekends, 12-14 h after each dose. Some samples of plasma obtained during the 8-d study with 300 mg were separated into lipoprotein fractions and analyzed for deuterated and unlabeled ␣-tocopherols as described previously (17, 18, 20, 21) .
Study of elective surgery patients
This study was carried out at the Eastman Center for Nutrition Research (ECNR), College of Medicine, East Tennessee State University (ETSU), Johnson City, TN, and the Surgical Service, Veterans' Administration Medical Center Hospital, Johnson City, TN, after approval of the Institutional Review Board (ETSU) and the Research and Development Committee, Veterans' Administration Medical Center Hospital. Written, informed consent was obtained from the selected elective surgery patients. Patients with biliary or lymphatic disease, hyperlipidemia, lipid malabsorption, jaundice, or chronic infection were excluded from the study, as were those who had received chemotherapy or radiation therapy.
Patient characteristics are shown in Table 1 . Each of the patients consumed one 150-mg capsule of the 1:1 mixture of deuterated ␣-TAc daily with breakfast until the day before surgery. Patients fasted 12-24 h before surgery. Subjects consumed the deuterated vitamin E for various lengths of time before surgery (Table 1) . Blood samples obtained from fasted subjects at entry into the study and at various times before and after surgery were collected, separated into plasma and red cell fractions, and stored at Ϫ70°C essentially as described earlier (18) . Tissue specimens obtained during surgery for diagnostic purposes were placed in cold, phosphate-buffered saline and transported to Laboratory Service for evaluation by a surgical pathologist. Excess remaining tissue was transported to the ECNR, where it was blotted dry, weighed, identified, and stored at Ϫ70°C in cryotubes until shipped with blood fractions on dry ice to the NRC, Ottawa, for analysis. Some of these samples were also analyzed for ␥-tocopherol.
Study of terminally ill patients
Two terminally ill patients, recruited specifically for the longterm study of natural compared with synthetic vitamin E uptake into tissue approved by the Institutional Review Board of the ETSU, gave informed, written consent for their participation. The two patients were each provided a daily dose of the 1:1 mixture of d 3 -RRR-␣-TAc and d 6 -all-rac-␣-TAc with breakfast (30 mg for one patient and 300 mg for the other). After pronouncement of death by a physician, the body of each patient was removed to the morgue for storage at Ϸ5°C. Each autopsy, carried out 10-14°C 1-3 h after death, took 1-2 h to complete. Tissue specimens were placed in cold, phosphate-buffered saline and transported to the ECNR, where the tissue was blotted dry, weighed, identified, and stored at Ϫ70°C in cryotubes until shipped with blood fractions on dry ice to the NRC, Ottawa, for analysis.
Extraction of tissues and fluids
Plasma tocopherols were extracted and analyzed essentially as described previously (8, 12, (29) (30) (31) . Bile and all tissues except adipose and skin were extracted by using the sodium dodecyl sulfate method (12, 29) . Adipose tissue and skin were saponified in alcoholic potassium hydroxide with 1% ascorbic acid before extraction (32) . The extracted tocopherol fraction was isolated from lipid extracts by injecting the concentrated extract containing the deuterated internal standards into a Varian (Varian Associates, Palo Alto, CA) model 5000 HPLC equipped with a Varian model 9090 autosampler, a Varian Fluorichrom fluorescence detector ( ex 220 nm, em 350 nm), a Foxy series 2130-00 series fraction collector (ISCO, Inc, Lincoln, NE), and a 5-m LiChrosorb Si 60 column (Merck, Darmstadt, Germany). The sample was eluted isocratically at 20°C with 90% heptane and 10% methyl t-butyl ether at a flow rate of 2 mL/min. The tocopherol fraction (␣ and ␥) eluting at 1.8-3.0 min was collected and stored at Ϫ20°C until required for GC-MS analysis.
Measurement of tocopherols
␣-Tocopherol samples were analyzed by GC-MS, mostly as their silyl ethers. The ␣-tocopherol fraction obtained after HPLC purification was taken to dryness under a stream of nitrogen gas, redissolved in silylation-grade pyridine (100 L) and bis(trimethylsilyl)trifluoroacetamide (50 L) with 1% trimethylchlorosilane and heated at 65°C in a closed vial for 15 min. Concentrations of d 0 -␣-tocopherol, d 3 -␣-tocopherol, and d 6 -␣-tocopherol were calculated from the peak areas of the corresponding parent ions in the mass spectrum relative to that of the d 9 -␣-tocopherol internal standard, after corrections were made for the isotopic purities of each deuterated ␣-tocopherol, where appropriate, and for the contributions of natural abundance isotopes (principally carbon and silicon). The latter correction applies only for isotopomer pairs differing by three atomic mass units (ie, d 0 and d 3 , d 3 and d 6 , and d 6 and d 9 ) and is calculated by subtracting either 2.4% or 0.6% of the peak area of the light isotopomer from the peak area of the heavy isotopomer of the silyl ether or the underivatized form of ␣-tocopherol, respectively. The GC-MS selected ion-monitoring mode was also used for the simultaneous analysis of ␣-tocopherols and d 0 -␥-tocopherol in some human tissue and fluid samples with d 17 -␥-tocopherol as the internal standard.
Statistical analyses
Data are reported in the text and in the figures as means ± SDs. Statistical analyses were carried out with SPSS 6.1 for the Macintosh (SPSS Inc, Chicago). Differences between concentrations of RRR-␣-tocopherol and all-rac-␣-tocopherol at individual time points in the human plasma kinetics study were tested for significance by conducting paired-comparison t tests. Onesample t tests also were used to test whether plasma RRR:rac dif- Table 5 Colon cancer A6690 644 69 --7.14 see Table 5 Pancreatic cancer fered significantly from the traditional value of 1.36. Tests for significance in changes in RRR:rac, unlabeled (d 0 ), and total deuterated ␣-tocopherol, and the percentage of deuterated ␣-tocopherol over time were performed by using repeated-measures analysis of variance.
RESULTS
Kinetics of RRR-␣-tocopherol compared with all-rac-␣-tocopherol in human plasma
Changes in plasma concentrations of ␣-tocopherols were studied in humans in response to supplementation with two different amounts (15 + 15 mg or 150 + 150 mg) of deuterated vitamin E (d 3 -RRR-and d 6 -all-rac-␣-TAc) given once (Figure 2 ) or eight times (Figure 3) .
Single 30-mg dose
Five subjects consumed a 30-mg dose of deuterated vitamin E (15 mg d 3 -RRR-␣-TAc and 15 mg d 6 -all-rac-␣-TAc) with their Sunday evening meal. Blood samples were obtained every morning for the next 5 d. The reproducibility and precision of the data were estimated by analyzing four replicate samples of plasma obtained from each of three subjects on day 2. The SD was 5% for d 3 -RRR-␣-tocopherol and d 6 -all-rac-␣-tocopherol and 2% for d 0 -␣-tocopherol.
Plasma concentrations of d 3 -RRR-␣-tocopherol were significantly greater than those of d 6 -all-rac-␣-tocopherol at all times (P < 0.001-0.05), with both forms of vitamin E declining steadily during the week from their maximal values at day 0 (Monday morning) of 1.5 ± 0.9 and 0.9 ± 0.5 mol/L, respectively ( Figure 2A ). Note that the statistical comparison of the two forms of vitamin E was made by using the paired values obtained simultaneously for each individual. This approach, made possible by the use of the two distinctly labeled forms of vitamin E, eliminates much of the variance that arises from factors influencing individual vitamin E concentrations and, consequently, group means and SDs.
RRR:rac was significantly > 1.36 at all times (P < 0.001-0.02), increasing from 1.63 ± 0.15 on day 0 to nearly 2 (1.96 ± 0.07) by day 4 (P < 0.01; Figure 2C ). Unlabeled ␣-tocopherol did not change significantly from its initial value of 20 ± 1 mol/L at day 0 ( Figure 2B ). Total ␣-tocopherol decreased slightly (P < 0.03), from 22 ± 2 mol/L on day 0 to 20 ± 1 mol/L on day 4.
The percentage of deuterated
was at a maximum (11 ± 6%) on day 0, decreasing to 4 ± 2% on day 4 (P < 0.001; Figure 2C ). On the first morning (day 0) the plasma concentrations of d 3 -RRR-␣-tocopherol (13 ± 3 mol/L) and d 6 -all-rac-␣-tocopherol (8 ± 3 mol/L) were a substantial fraction of the total ␣-tocopherol (34 ± 7 mol/L). The percentage of deuterated ␣-tocopherol declined from its maximal value of 55 ± 8% on day 0 to 25 ± 6% on day 4 ( Figure 2F ; P < 0.001). Although the concentration of unlabeled ␣-tocopherol remained unchanged, the total ␣-tocopherol concentration in plasma decreased significantly throughout the week because of the loss of the deuterated ␣-tocopherols (P < 0.001). The concentrations of d 3 -RRR-␣-tocopherol were significantly greater than those of d 6 -all-rac-␣-tocopherol on every day (P < 0.001), with RRR:rac, initially 1.57 ± 0.09 on day 0, rising to 2.0 by the end of the week (1.97 ± 0.04 on day 4; P < 0.001). RRR:rac values were > 1.36 at all times (P < 0.001-0.01).
Eight daily 30-mg doses
A second group of five subjects consumed a total of eight 30-mg doses of deuterated vitamin E at the rate of one per day on consecutive days, starting with their Sunday evening meal (Figure 3 , A-C; day Ϫ7 to day 0). During this time the increase in both forms of deuterated ␣-tocopherol ( Figure 3A ) was accompanied by a corresponding decrease of the unlabeled ␣-tocopherol ( Figure 3B ; P < 0.001), thereby dampening the net change in total ␣-tocopherol (the trends are more sharply illustrated in Figure 4 , A-B, representing the data for one individual). At the end of the dosing period (ie, on day 0), the concentrations of both deuterated ␣-tocopherols had begun a rapid decline and, by day 7, had declined to below the concentrations seen on day Ϫ7 ( Figure 3A) . The percentage of deuterated ␣-tocopherol increased from 11 ± 5% on day Ϫ7 to 33 ± 6% on day 0 and dropped back to 10 ± 2% by day 7 ( Figure 3C ).
The concentration of d 3 -RRR-␣-tocopherol was always significantly greater than that of d 6 -all-rac-␣-tocopherol (P < 0.001-0.03). RRR:rac quickly rose from its lowest value of 1.48 ± 0.25 on day Ϫ7 to 1.9 ± 0.1 by day 0, staying at that value for the remainder of the Note that time is plotted on a log scale and that G is a log-log plot. Symbols are as described in Figure 2 . T, tocopherol.
by guest on May 29, 2014 ajcn.nutrition.org Downloaded from study. RRR:rac exceeded 1.36 after the first day of dosing (ie, by day Ϫ6; P < 0.001-0.01). The constancy of the RRR:rac from day 1 onward indicated that the two labeled tocopherols disappeared from plasma at the same rate after dosing ended.
Eight daily 300-mg doses
More than 1 mo after the previous study, the same group of subjects consumed 300 mg/d of the 1:1 mixture of deuterated ␣-tocopherols for 8 d. Plasma vitamin E concentrations were followed for > 500 d (Figures 3, D-I ). The percentage of deuterated ␣-tocopherol reached a peak of 80 ± 5% between days Ϫ3 and 0, which was followed by an initially rapid decline to 35 ± 8% by day 7 ( Figure 3F ). However, the rate of decline thereafter slowed substantially, with the deuterated tocopherols still comprising as much as 2.5% of the total plasma ␣-tocopherol > 17 mo later (Figure 3I) . The slowing of the disappearance of the deuterated tocopherols and their continued persistence are consistent with the return of deuterated vitamin E to plasma from tissues.
At this highest dosage, the effect of the newly absorbed deuterated vitamin E on unlabeled ␣-tocopherol was most evident (Figure 3E) , particularly on an individual basis ( Figure 4E ). The mean plasma concentration of d 0 -␣-tocopherol decreased from 17.4 ± 9.4 mol/L on day Ϫ7 to 8.7 ± 5.3 mol/L on day 0 (P < 0.02) and did not return to normal until day 7. The large influx of deuterated vitamin E caused the mean total ␣-tocopherol to increase from 36 ± 13 mol/L on day Ϫ7 to 46 ± 19 mol/L on day Ϫ3 (P < 0.04), which was followed by a decrease to 25 ± 10 mol/L by day 7 (P < 0.02).
The concentration of d 3 -RRR-␣-tocopherol was significantly greater than that of d 6 -all-rac-␣-tocopherol at nearly all times (P < 0.001-0.05; P > 0.05 for days 50, 150, and 507 only). During the dosing period RRR:rac was constant at 1.51 ± 0.11, being significantly > 1.36 from day Ϫ6 onward (P < 0.02-0.05). After supplementation ended, this ratio increased sharply to 2.01 ± 0.12 by day 7 ( Figure 3F ) and stayed constant at a value of 2.00 ± 0.13 for Ϸ 100 d (ie, up to day 106) by which time the percentage of deuterated ␣-tocopherol had declined to 5% ( Figure 3I ).
The increase in the RRR-rac ratios immediately after dosing ended reflects the more rapid disappearance of all-rac-␣-tocopherol during this period; by day 3 the d 6 -all-rac-␣-tocopherol concentration had declined to the value observed on day Ϫ7, whereas it took until day 4 before the RRR-␣-tocopherol concentration had declined to its day Ϫ7 value (Figure 3D ). After > 100 d RRR:rac appeared to decrease ( Figure 3I ), but this may have been an experimental artifact arising from the relatively small quantities of the deuterated ␣-tocopherols remaining (< 5%). . Note that time is plotted on a log scale and that G is a log-log plot. Symbols are as described in Figure 2 .
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During this study a limited opportunity arose to examine lipoprotein fractions. VLDL, LDL, and HDL were obtained on day 43 of the 8-d study with 300 mg. RRR-rac ratios and the percentage of deuterated ␣-tocopherol showed, for each individual, a high degree of uniformity between the lipoprotein fractions, with the RRR-rac ratios all being close to 2.0 ( Table 2) . In contrast, the results obtained for blood sampled at day Ϫ3 from an individual who was not a part of the main study (subject NRC-11) showed a trend of increasing enrichment of RRR-␣-tocopherol compared with all-rac-␣-tocopherol in the direction chylomicrons < VLDL < LDL, HDL.
Single 100-mg dose
In a third group given 100 mg of the 1:1 mixture of deuterated vitamin E in which the deuterium labeling of the two vitamin E forms was reversed, RRR:rac in plasma again reached a maximum value of 2:1 (data not shown). This result indicates that the presence of the deuterium label in the molecule does not contribute in any significant way to the observed discrimination between RRR-␣-tocopherol and all-rac-␣-tocopherol.
Study of elective surgery patients
The subjects recruited into the study were distributed into six groups and were given 150 mg of the 1:1 mixture of deuterated vitamin E daily for nominal periods of 3, 8, 14, 21, 29, and 41 d before surgery, respectively. The mean plasma d 0 -␣-tocopherol concentration just before dosing began; the mean d 0 -␣-tocopherol and total ␣-tocopherol concentrations, the percentage of deuterated ␣-tocopherol, and RRR-rac ratios at the time of surgery; the RRR-rac ratios over the period beginning ≥ 5 d after surgery; and ␥-tocopherol measured over the duration of the study are shown in Table 3 .
The trends already noted in the NRC plasma kinetics study were also apparent in this study, although the changes were not significant, unless noted otherwise. For example, plasma d 0 -␣-tocopherol concentrations of patients were consistently lower at the end of supplementation, the decrease being larger the longer the period of dosing. This finding was found to be significant, not by a paired t test of the individual concentrations but by a one-sample t test of the ratio of the d 0 -␣-tocopherol concentrations (before:after > 1, P = 0.002).
Plasma total and the percentage of deuterated ␣-tocopherol increased with the duration of dosing. RRR-rac ratios generally increased after the dosing ended (ie, after ≥ 5 d), attaining values close to 2.0 for all but the first group. The rise in the RRR-rac ratio after dosing ended was highly significant, as determined by a one-sample t test [RRR:rac (≥ 5 d after surgery)/RRR:rac (end of dosing) > 1, P < 0.0005].
Tissues obtained during elective surgery included adipose (n = 19), muscle (n = 8), skin (n = 6), vein (n = 3), and nerve (n = 3) ( Table 1 ). For each tissue examined, the mean length and range of dosing time, the corresponding mean concentrations of labeled and unlabeled ␣-tocopherols and ␥-tocopherol (where available), and, for comparison, the corresponding values measured for plasma obtained at the time of surgery are given in Table 4 .
TABLE 2
Plasma concentrations of unlabeled and deuterated ␣-tocopherols in plasma lipoproteins from subjects participating in plasma kinetic studies 1 Subjects took 300 mg of a 1:1 mixture of d 3 -RRR-and d 6 -all-rac-␣-tocopheryl acetate daily with an evening meal. Blood from subject NRC-11, a 42-y-old woman who was not part of the main study, was obtained ഠ15 h after she took the fifth capsule (ie, on day -3). Blood from the other subjects was obtained on day 43. T, tocopherol.
Subject and fraction
2 Ratio of d 3 -RRR-to d 6 -all-rac-␣-tocopherol.
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Tissues showed a wide range in the mean concentrations of labeled and unlabeled ␣-tocopherols and, thus, the percentage of deuterated ␣-tocopherol, whereas the corresponding values for plasma showed much less variation, despite the substantially different lengths of time dosing was carried out (Figure 5B) . Similarly, tissues showed more variability than plasma in their mean RRR-rac ratios ( Figure 5A ).
The higher variability in the percentage of deuterated ␣-tocopherol and RRR:rac in tissues compared with plasma is not an experimental artifact caused by, for example, adventitious oxidation after surgical removal of tissue samples or during sample processing and extraction. This was confirmed by our experience in handling many thousands of animal tissue samples in the NRC laboratory over a period of almost 10 y, during which time samples were analyzed repeatedly after successive freeze-thaw cycles with extended periods of storage in between. Excellent reproducibility of results was obtained. In the present study numerous tissue results were confirmed by repeating the complete analysis and even by analyzing duplicate samples stored for safekeeping and backup purposes at the ETSU laboratory. Whereas there is no doubt that oxidation would eventually destroy tissue tocopherol if tissue were exposed to conditions such as prolonged standing at room temperature, opportunities for this were minimized in both the study of the elective surgery patients and the study of the terminally ill patients. Furthermore, even if oxidative degradation were to occur, it is unlikely that it would differentially affect one or the other forms of deuterated ␣-tocopherol, ie, RRR:rac should not change.
Plots of the distributions of d 0 -␣-tocopherol, the percentage of deuterated ␣-tocopherol, RRR:rac, and the percentage of ␥-tocopherol values determined for all tissues and plasma obtained from all subjects at the time of surgery are shown in Figure 6 . The magnitude and enormous variability of d 0 -␣-tocopherol in adipose tissues, and to a lesser extent in other tissues, contrasts with the small range of values seen in plasma. The highest ␣-tocopherol concentrations were seen in adipose tissues.
An unexpected result shown in Table 4 and Figure 6 is the substantially higher percentage of ␥-tocopherol (ie, percentage of ␥-tocopherol, defined relative to total unlabeled tocopherols; see footnote 3 in Table 4 ) found in a significant portion of the tissue samples compared with the corresponding value for plasma tocopherols at either the time of surgery or before the start of dosing. The drop in the percentage of plasma ␥-tocopherol during supplementation indicated, by the very definition of the term, that supplementation with deuterated ␣-tocopherol produced a proportionately larger decrease in the plasma concentration of ␥-tocopherol than of d 0 -␣-tocopherol.
Study of terminally ill patients
A proper evaluation of the relative uptake and retention of natural compared with synthetic vitamin E requires measurements in a broad range of tissues after a relatively long period of consumption of these two forms of vitamin E. To carry out such a study, we enlisted two terminally ill subjects (Table 1) . One subject (patient 1422) took 30 mg of the 1:1 mixture daily for 361 d; the other subject (patient A6690) took 300 mg/d for 615 d. At death, an autopsy was performed to obtain various tissues that were analyzed for d 0 -, d 3 -, and d 6 -␣-tocopherol in the usual way. The concentration of deuterated and unlabeled ␣-tocopherol, the RRR-rac ratios, and the percentage of deuterated ␣-tocopherol in tissues, plasma, and erythrocytes at the time of autopsy for both patients are given in Table 5 . Although only one subject was studied for each dose, some remarkable observations were made.
Patient 1422, who received 30 mg vitamin E/d for almost 1 y, had low tissue concentrations of deuterated ␣-tocopherols; the percentage of deuterated ␣-tocopherol was in the range 2-11%, with a mean value of 5.9 ± 2.2%. Thus, in this patient, supplementation with 30 mg/d apparently had little effect on either plasma or tissue total ␣-tocopherol concentrations. RRR:rac averaged 1.71 ± 0.24 for all tissues sampled, with the plasma ratio being slightly higher (2.06).
Tissue concentrations of deuterated ␣-tocopherols were much higher in patient A6690, who received 300 mg vitamin E/d for Where the number of samples exceeds the number of subjects, the group mean was calculated as the average of the individual subject means. 4 First number in brackets is the number of subjects; the second number is the number of samples. Plasma samples were obtained during the entire study (ie, during and after dosing).
␣-T ␣-T Before dosing End of dosing At surgery ≥ 5 d after surgery
5 % ␥-T = 100 ϫ ␥-T/ (␥-T + d 0 -␣-T), ie, the percentage of total unlabeled tocopherol that is ␥-T. 6 x -± SD. 7 The SD was calculated from the values obtained at different times for the one subject. 8 Significantly different from value at time of surgery, P < 0.005 (paired t test). 9 The SD was replaced by a value that is half the difference between the two numbers.
by guest on May 29, 2014 ajcn.nutrition.org At surgery Before dosing almost 2 y. The percentage of deuterated ␣-tocopherol was in the range 41-77%, with a mean value of 65 ± 10%. RRR:rac averaged 2.01 ± 0.17 for all tissue samples, a value that was similar to the ratio in plasma, 2.11. In this patient, total ␣-tocopherol in plasma and many of the tissues was more than double the concentration found in patient 1422. For example, the percentage of deuterated ␣-tocopherol in plasma was 6.3% in patient 1422 and 68% in patient A6690, with the corresponding d 0 -and total ␣-tocopherol concentrations being 16 and 19 mol/L and 17 and 60 mol/L, respectively. Taking the comparison between the two patients at face value, vitamin E supplementation with 300 mg/d (ie, 354 IU containing 150 + 75 = 225 mg 2R-␣-tocopherol stereoisomers) apparently increased plasma concentrations of ␣-tocopherol by a factor of three and at least doubled the concentrations in most tissues. Compared with patient 1422, patient A6690 showed less variability in both the tissue RRR-rac ratios and in the percentage of deuterated ␣-tocopherol, which were close to the corresponding plasma values. This implies the existence of a greater degree of equilibration between tissues and plasma in patient A6690 due, presumably, to the 250 additional days of dosing, the larger dose, or both. The convergence of the plasma and tissue values for these two indexes in patient A6690 contrasts with the results obtained with the elective surgery patients, who were dosed for much shorter periods of time.
DISCUSSION
This study was undertaken to evaluate the response of human plasma and tissues to vitamin E given in amounts and forms commonly consumed as dietary supplements. The 30-mg dose is similar to the amount found in multiple vitamin supplements and the 300-mg (354-IU) dose is comparable with the amount commonly found in vitamin E capsules (eg, 400 IU).
Natural and synthetic forms of ␣-tocopherol were compared in plasma via competitive uptake from 1:1 mixtures of RRR-␣-TAc and all-rac-␣-TAc. Total ␣-tocopherol concentrations in plasma increased only slightly when a 30-mg dose of the two forms of vitamin E was given once or on 8 successive days. However, it can be inferred from the decline to baseline concentrations shown in Figures 2E and 3E that the total ␣-tocopherol concentration in plasma increased by Ϸ50% and Ϸ100% when a 300-mg dose was given once and on 8 successive days, respectively. These data confirm results obtained previously with unlabeled vitamin E (33-37).
One of the most obvious advantages that accrue with the use of deuterated vitamin E is that the newly absorbed vitamin can readily be distinguished from the preexisting, unlabeled ␣-tocopherol. For example, by the first morning after administration of the labeled vitamin E with an evening meal, a 30-mg dose produced 11% deuterated ␣-tocopherol in the plasma ( Figure 2C ) and 33% when the same dose was given for 8 consecutive days (day 0; Figure 3C ). The first morning after a 300-mg dose there was 55% deuterated ␣-tocopherol in the plasma ( Figure 2F ), and this rose to 80% after dosing for 8 consecutive days (day 0; Figure 3F ).
One of our most striking findings was the speed with which the new (labeled) vitamin E became a large fraction of the vitamin E in plasma after a single 300-mg dose. It appears that there is a rough homeostasis of vitamin E in plasma so that when new vitamin E is absorbed it displaces old vitamin E. As a consequence, the 300-mg dose taken for 8 consecutive days produced a relatively small increase in total ␣-tocopherol in plasma (Figure 3E) . Because the body cannot distinguish between deuterated and nondeuterated ␣-tocopherol per se, our results show that vitamin E homeostasis was achieved by the loss of old vitamin E from the plasma lipoproteins when there was an abundance of new vitamin E arriving in the chylomicrons. Exactly how this homeostasis is controlled is unknown. However, it seems likely that it is dependent on the hepatic ␣-tocopherol transfer protein, which preferentially selects RRR-␣-tocopherol for secretion into nascent VLDL (12, (17) (18) (19) (20) 38) . A genetic defect in this protein causes low plasma ␣-tocopherol concentrations (39) , vitamin E deficiency (26) , and an impaired ability to discriminate between stereoisomers of ␣-tocopherol (21) .
A second advantage conferred by the deuterated vitamin E technique is that the two distinctly labeled RRR-and all-racforms can be compared directly and simultaneously in the same subject, which greatly increases the statistical power of the data by eliminating much of the variations attributable to individual differences and factors that change with time. The benefits are twofold: 1) the relative availabilities of RRR-␣-tocopherol and all-rac-␣-tocopherol are immediately evident in each and every subject at any time, and 2) following the time dependence of the RRR-rac ratio provides insight into the mechanisms in the body for absorbing, distributing, and eliminating vitamin E. The behavior of the RRR-rac ratios also supports a stereoselective mechanism for the recycling of ␣-tocopherol through the liver. The initial RRR-rac ratio in plasma was Ϸ1.5 the morning after a single dose of either 30 mg or 300 mg of the two deuterated ␣-TAcs ( Figures 2C and 2F) , and it was not much different after eight doses of 30 mg and 300 mg ( Figures 3C and 3F) . However, after dosing ceased, the RRR-rac ratio increased to Ϸ2. Because the RRR-rac ratio is smaller during dosing than afterward, it is likely that plasma and tissues (see below) acquire some 2S-␣-tocopherol stereoisomers during the dosing period. These 2S stereoisomers, which, of course, constitute 50% of all-rac-␣-TAc, are preferentially eliminated after dosing ceases, presumably by a differential filtration in an overall and continuous recycling process involving the liver and its ␣-tocopherol transfer protein.
After the dosing period, the percentage of deuterated ␣-tocopherol in plasma declined rapidly. For example, the percentage of deuterated ␣-tocopherol in plasma decreased from 80% to < 20% in 2 wk after daily dosing with 300 mg of deuterated material for 8 successive days ( Figure 3F ). This must reflect the replacement and dilution of circulating ␣-tocopherol by newly ingested unlabeled vitamin E and by unlabeled ␣-tocopherol stored in the tissues. These observations are consistent with a rapid recycling of RRR-␣-tocopherol and the conclusion that the liver secretes approximately one plasma pool of ␣-tocopherol into the plasma daily (23) .
There are relatively few data available regarding ␣-tocopherol concentrations in human tissues (32, (40) (41) (42) (43) (44) . The present results add substantially to knowledge in this area. For the elective surgery patients the tissue RRR-rac ratios were, except for the liver, generally slightly lower than plasma RRR-rac ratios (Table  4 and Figure 5A ). For tissues other than the liver, the RRR-rac ratios cluster around 1.5 (compared with 1.7 for plasma), a value that slightly exceeds the officially accepted relative biopotencies of these two forms of vitamin E of 1.36 (7) . The single sample of liver examined had an RRR-rac ratio of 0.91 after 7 d of dosing (compared with 1.79 for plasma; Table 4 ). A low (< 1.0) ratio for liver was expected on the basis of earlier continuous feeding, competitive studies with an equimolar mixture of d 6 -RRR-␣-TAc and d 3 -SRR-␣-TAc with the rat as the experimental animal (12) . For example, in the study by Ingold et al (12) , the RRR-SRR ratio in the liver was 0.67 after 8 d.
The percentage of deuterated ␣-tocopherol in the tissues declined through the following series: liver > gallbladder > vein > skin > muscle > adipose tissue > nerve, with the percentage in plasma being the same as in the liver ( Figure 5B ). These results are consistent with those of earlier studies on animals continuously fed deuterated RRR-␣-TAc (12, 16) . The times required for new deuterated RRR-␣-tocopherol to become equal in concentration to old nondeuterated RRR-␣-tocopherol in plasma, liver, muscle, and brain were 3.7, 3.0, 24, and 107 d, respectively, for guinea pigs and 6.2, 6.9, 23, and 40 d, respectively, for rats (16) . Insofar as comparison is possible, therefore, the kinetics of vitamin E in human tissues (ie, the relative rates of uptake of new vitamin E) are similar to those in two other species of mammals. Although the American diet contains 5-10 times as much ␥-tocopherol as ␣-tocopherol, there have been few measurements of ␥-tocopherol in human tissues and these have been largely confined to adipose tissue (43) . The data obtained from the elective surgery study show that ␥-tocopherol represents Ϸ31% of adipose tissue vitamin E (unlabeled). More remarkable is the 38% contribution of ␥-tocopherol to muscle vitamin E and the 53% contribution to skin vitamin E ( Table 4 ). The contribution of ␥-tocopherol to plasma vitamin E was 19 ± 7% (range: 8-28%). This percentage refers to measurements before supplementation with deuterated ␣-tocopherol because supplementation is known to reduce plasma ␥-tocopherol concentrations (Table 4) (45, 46) . At the time of surgery the mean percentage contribution of ␥-tocopherol to plasma vitamin E was 14 ± 5% (range: 5-18%; Table 4 ). The unexpectedly high tissue concentrations of ␥-tocopherol invite reexamination of the potential importance of this previously underestimated component of vitamin E, particularly in view of the recent report that ␥-tocopherol reacts with the pollutant, nitrogen dioxide, in a way fundamentally different to that of ␣-tocopherol (47) .
In marked contrast with the elective surgery results, the terminally ill patients who took the deuterated ␣-tocopherols for much longer periods of time attained an RRR-rac ratio close to 2:1 in plasma and in all tissues (particularly patient A6690, who took the 300-mg supplement daily for almost 2 y; Table 5 ). Note also that the tissue concentrations of ␣-tocopherol in subject A6690 were much greater (generally by a factor of տ 2) than those in patient 1422, who took a 30-mg supplement daily for nearly 1 y (Table 5) . Moreover, the patient receiving the 300-mg dose had Ϸ65% deuterated ␣-tocopherol throughout his body, whereas the patient receiving the 30-mg daily dose had only Ϸ6% deuterated ␣-tocopherol in his body. Thus, the larger dose significantly increased ␣-tocopherol concentrations in all tissues, including the brain. Another striking result from these long-term dosing studies was the general similarity of the RRR-rac ratios and the percentage of deuterated ␣-tocopherol between plasma and tissues in both patients. It is clear, given sufficient time (1-2 y) , that tissues eventually equilibrate with the various forms of ␣-tocopherol circulating in the plasma (as is expected).
There also are striking differences between the two patients in the concentrations of ␣-tocopherol in some of the tissues. For example, although plasma total ␣-tocopherol in patient A6690 was 3.5 times that in patient 1422, the relative difference in concentrations was sevenfold for the left ventricle, ninefold for the right atrium, sixfold for liver, and ninefold for the tail of pancreas. (We have no explanation for the large difference between the head and tail of the pancreas in patient A6690.) It is difficult to draw conclusions from data obtained from just two patients. The only other data we are aware of in which the effect of dosing on concentrations in human tissues (other than adipose) has been examined was obtained in a limited study carried out by us using patients undergoing elective heart surgery. In this study, doses of 100-900 mg d 3 -RRR-␣-TAc given orally for 14 consecutive days caused a twofold increase in myocardial vitamin E concentrations (48) .
In patient A6690 the RRR-rac ratio in bile was as high as the value determined in plasma. This finding is supported by results we obtained in bile collected from rats and humans fed 1:1 mixtures of RRR-and SRR-␣-TAc (ie, RRR > SRR; unpublished observations). Evidently, the 2S stereoisomers were not preferentially eliminated from the body as unchanged tocopherol excreted from the liver in bile.
The hydrophobic, water-insoluble nature of vitamin E and the absence of a specific plasma protein carrier means that its delivery to tissues must, by default, occur via lipoprotein-mediated mechanisms. Delivery to tissues has been suggested to take place via lipoprotein lipase-mediated transfer (49), LDL receptormediated uptake of LDL (50) , and aqueous phase-mediated transfer from HDL (51) . There is also evidence for a phospholipid transfer protein-mediated exchange between lipoproteins and tissue (52) . None of these mechanisms have as yet been shown to involve preferential transfer of one particular stereoisomeric form of ␣-tocopherol. The differences in discrimination between RRR-␣-tocopherol and roughly half the stereoisomers present in all-rac-␣-tocopherol in plasma and the various tissues can most simply be explained by invoking a dual pathway for delivery of ␣-tocopherol to tissues, as was originally suggested in the first kinetics study using two deuterated ␣-tocopherol stereoisomers (RRR and SRR) (12) .
After absorption of all the various forms of vitamin E, including RRR-␣-tocopherol, from the intestine, apparently without discrimination (18, 20, 53) , they may each be delivered without discrimination directly to tissues via the lipoprotein lipase-mediated hydrolysis of chylomicrons (49) . Thus, tissues to which vitamin E is delivered mainly by chylomicrons and the lipoprotein lipase route (49) are likely to become enriched with all stereochemical and structural forms of vitamin E, including ␥-tocopherol, and not enriched just with RRR-␣-tocopherol. The high concentrations of ␥-tocopherol in adipose tissue and skin obtained from the elective surgery patients suggest that these tissues receive a particularly large fraction of their vitamin E from chylomicrons. The relatively low RRR:rac in muscle (1.40) also suggests that this tissue takes up much of its vitamin E from chylomicrons.
After the delivery of chylomicron remnants to the liver, it appears probable that the hepatic ␣-tocopherol transfer protein preferentially enriches nascent VLDL with RRR-and probably the other 2R-␣-tocopherol stereoisomers (12, 18, 19) . The 2R-␣-tocopherol stereoisomers are then delivered to tissues by one or more of the mechanisms outlined above. The net RRR:rac in each tissue will be a composite that initially reflects the relative contribution from chylomicron donors (all forms of vitamin E) and the VLDL-derived vitamin E (mainly 2R-␣-tocopherol stereoisomers). Ultimately, RRR:rac becomes 2:1. The rate at which this ultimate value is attained in a tissue will depend on tissue clearance mechanisms, which are still unknown. This general model for ␣-tocopherol uptake and retention is consistent with data from the literature (18, 19) and with the lipoprotein results obtained during the dosing period (Table 2) , which show only slight enrichment of RRR-␣-tocopherol in chylomicrons but progressive enrichment in VLDL, LDL, and HDL.
In earlier competitive dosing studies with 1:1 mixtures of deuterated RRR-and SRR-␣-TAcs, we found a strong preferential retention of RRR-␣-tocopherol in plasma, erythrocytes, and tissues (except liver) of rats (12) and monkeys (19) and in plasma and erythrocytes of humans (18, 20, 21) . For example, in rats continuously fed an equimolar mixture of deuterated RRR-(d 6 ) and SRR-(d 3 )-␣-TAc, the RRR-SRR ratio increased with time, reaching 2.4 in plasma and 5.3 in the brain after 22 wk (12). Similarly, an equimolar single dose of these same two labeled ␣-TAcs given to humans produced an RRR-SRR ratio in plasma of 6.7 ± 2.8 4 d later (18) . In the present study, the RRR-rac ratio after a 300-mg daily dose for 8 d stabilized for months at Ϸ2.0, some 7 d after the end of dosing ( Figure 3I ).
All our competitive uptake and retention studies indicate that it is the stereochemistry at the 2-position that is the prime determinant of biodiscrimination between stereoisomers of ␣-tocopherol. That is, ultimately all four 2R stereoisomers will be preferentially retained (included among these is RRR-␣-tocopherol-natural vitamin E) and all four 2S stereoisomers will be preferentially eliminated from the body. That is, eventually, just half of a dose of synthetic vitamin E would be treated by animals and humans as although it were the natural vitamin and the other half would be eliminated from the liver via the bile, or from the kidney via the urine, or both.
Attractive as this simple explanation is for a 2:1 RRR-rac ratio, it may not fully reflect the real situation. For example, the acetate esters of all eight ␣-tocopherol stereoisomers have been reported to be active in the traditional rat fetal gestation-resorption assay (2). They not only were reported to have different activities from each other but, also, the relative biopotencies appeared not to be exclusively dependent on the stereochemistry at the 2-position (RRR > RRS > RSS > SSS > RSR > SRS > SRR > SSR), although the 2R stereoisomers generally appear to be more active than 2S forms (2) . It follows, then, that within the organs and tissues critical to the bioassay, there will be a finite amount of each stereoisomer present, at least for the duration of the test. Indeed, a recently published bioavailability study carried out in rats dosed with all-rac-␣-TAc for 90 d showed the presence of 2S stereoisomers in tissues and plasma (54) . However, there was a preferential accumulation of each of the four 2R stereoisomers (70-86%), confirming the dominant importance of the chiral center at the 2-position.
As was suggested in the first study that used deuterated tocopherols (12) , the stereoselection among ␣-tocopherol stereoisomers is probably mediated by the hepatic tocopherol transfer protein. The observation in competitive uptake studies of initially higher concentrations of 2S stereoisomers present only in the liver of rats (12) and apparently of humans (Table 4) points to a critical role of the liver in the process of stereoselection. The available evidence indicates that stereochemistry is the major, if not the only, determinant of ␣-tocopherol bioavailability, which, in turn, is strongly linked to biopotency.
Although the liver-mediated stereoselection mechanism operates continuously on all tocopherols entering the liver (both newly absorbed and recirculated) and quickly establishes its maximum effect in plasma, the effect on stereoisomeric ratios (ie, RRR:rac) in individual organs and tissues will depend on the specific rates of transfer of ␣-tocopherol into and out of each organ. For this reason alone, the short period of dosing typical of the traditional type of bioassay makes this assay of questionable relevance to the real-world situation for both rats and humans (8) .
In conclusion, the present work showed that the bioavailability of synthetic all-rac-␣-tocopherol is roughly half that of natural RRR-␣-tocopherol, at least in the long term. This may also be true in the short term after cessation of dosing. This raises obvious questions about the validity for humans and animals of the "official" relative biopotencies, eg, RRR-␣-TAc:all-rac-␣-TAc = 1.36:1.00 (7). It seems highly improbable that the official biopotency ratio is relevant to human needs, which might be better served by thinking in terms of a 2:1 ratio, as was first suggested Ϸ18 y ago in this Journal (55) .
